{"id":"apitox-pure-honeybee-toxin","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions (pain, swelling, erythema)"},{"rate":null,"effect":"Allergic reactions / anaphylaxis risk"},{"rate":null,"effect":"Systemic inflammatory response"}]},"_chembl":{"chemblId":"CHEMBL4176158","moleculeType":"Small molecule","molecularWeight":"320.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Honeybee venom contains multiple bioactive peptides, primarily melittin and phospholipase A2, which interact with cell membranes and immune receptors to suppress pro-inflammatory cytokine production and modulate T-cell and macrophage function. The venom's mechanism involves both direct antimicrobial activity and indirect immune regulation, potentially useful in inflammatory and autoimmune conditions. Apitoxin has been studied for its analgesic and anti-arthritic properties in preclinical and early clinical settings.","oneSentence":"Apitoxin, the active component of honeybee venom, exerts anti-inflammatory and immunomodulatory effects through phospholipase A2 and other peptide components that modulate immune cell activity and reduce inflammatory mediators.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:42:49.623Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory joint disorders"}]},"trialDetails":[{"nctId":"NCT03710655","phase":"PHASE3","title":"Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients","status":"UNKNOWN","sponsor":"Apimeds, Inc.","startDate":"2019-04","conditions":"Multiple Sclerosis","enrollment":468},{"nctId":"NCT00949754","phase":"PHASE2","title":"Apitox, Honeybee Venom Treatment for Osteoarthritis Pain and Inflammation","status":"COMPLETED","sponsor":"Apimeds, Inc.","startDate":"2009-10","conditions":"Osteoarthritis of the Knee","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Apitoxin"],"phase":"phase_3","status":"active","brandName":"Apitox - pure honeybee toxin","genericName":"Apitox - pure honeybee toxin","companyName":"Apimeds, Inc.","companyId":"apimeds-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Apitoxin, the active component of honeybee venom, exerts anti-inflammatory and immunomodulatory effects through phospholipase A2 and other peptide components that modulate immune cell activity and reduce inflammatory mediators. Used for Rheumatoid arthritis, Inflammatory joint disorders.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}